Xian Shen advises life sciences clients on health economics and outcomes research initiatives that support product commercialization and demonstrate product value.

She has strong quantitative research skills and is an experienced user of Medicare data, especially the prescription drug event data and associated Part D benefit design and plan characteristics files.

By combining her pharmacy background and analytic expertise, Xian provides clients with data insights on utilization and economic outcomes of pharmaceutical treatments using large healthcare databases. She works with clients on policy issues regarding the Medicare Part D program, medication access, and pharmacy-related quality and value initiatives.

Xian is completing her PhD in pharmaceutical health services research at the University of Maryland. She has an MS from the University of Maryland and a BS in pharmacy from China Pharmaceutical University.

Authored Content

New Avalere research finds that health plan members enrolled in plans that cover abuse-deterrent formulations (ADFs) of opioids have a lower risk of opioid abuse (OA) and overdose (OD) and lower opioid abuse-related hospitalizations than people in plans that do not offer coverage of ADF opioids.